

# Vietnam

# **Country Operational Plan**

FY 2018



## **Budget Summary Reports**

### Summary of Planned Funding by Agency and Funding Source

Agency	GAP	Funding Source GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
State		625,000		625,000	0	625,000
USAID		12,197,126		12,197,126	941,274	13,138,400
DOD		459,968		459,968	1,022,113	1,482,081
HHS/CDC	1,857,750	11,671,214		13,528,964	2,647,802	16,176,766
HHS/SAMHSA		1,365,503		1,365,503	0	1,365,503
State/EAP		30,000		30,000	0	30,000
Total	1,857,750	26,348,811	0	28,206,561	4,611,189	32,817,750

## Summary of Planned Funding by Budget Code and Agency

	Agency							
Budget Code	State	State/EAP	DOD	HHS/CDC	HHS/SAMH SA	State/SGAC	USAID	Total
CIRC		0	0	0	0		0	0
НВНС		0	47,857	51,263	0		412,249	511,369
нкір		0	0	0	0		0	0
HLAB		0	63,794	478,510	0		0	542,304
HMBL		0	0	0	0		0	0
HMIN		0	44,877	0	0		0	44,877
HTXD		0	0	0	0		47,428	47,428
HTXS		0	18,838	3,807,594	0	0	2,354,053	6,180,485
HVAB		0	0	0	0		0	0
нуст	6,333	0	55,506	1,851,548	0		1,550,369	3,463,756
HVMS	593,333		86,549	3,519,126	314,547		1,589,425	6,102,980

Custom 2018-09-07 15:52 EDT Approved



	625,000	30,000	459,968	13,528,964	1,365,503	0 12,	197,126	28,206,561
PDTX		0	0	0	0		97,134	97,134
PDCS		0	0	0	0		97,134	97,134
OHSS	12,667	30,000	6,797	550,692	278,208	1,	558,661	2,437,025
МТСТ		0	2,266	0	0		0	2,266
IDUP		0	0	92,972	772,748		560,946	1,426,666
HVTB		0	2,266	106,813	0		497,800	606,879
HVSI		0	14,245	1,686,843	0		587,420	2,288,508
HVOP	12,667	0	116,973	1,383,603	0	2,	844,507	4,357,750

Approved



## **Technical Areas**

## **Technical Area Summary**

#### Technical Area: Care

Budget Code	Budget Code Planned Amount
НВНС	427,330
нкір	0
нутв	517,200
PDCS	97,134
Total Technical Area Planned Funding:	1,041,664

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	325,164
HVSI	1,751,080
OHSS	1,739,700
Total Technical Area Planned Funding:	3,815,944

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
нмім	40,346
НVАВ	0
нуст	3,032,900
HVOP	4,143,335
IDUP	1,016,182
мтст	0
Total Technical Area Planned Funding:	8,232,763





#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount
нтхр	0
HTXS	4,993,399
PDTX	97,134
Total Technical Area Planned Funding:	5,090,533



## **Technical Area Summary Indicators and Targets**

Indicator Number	Label	2019
	PrEP_NEW_DSD Number of	
	individuals who have received	
	antiretroviral pre-exposure	n/a
	prophylaxis (PrEP) to prevent HIV	
	infection in the reporting period.	
	Number of individuals who have	
	been newly enrolled on oral	
	antiretroviral pre-exposure	5,610
	prophylaxis (PrEP) in the reporting	
	period to prevent HIV infection	
	Male 15-19	128
	Male 20-24	1,471
	Male 50+	62
	Female 15-19	46
PrEP_NEW_DSD	Female 20-24	496
	Female 50+	30
	FSW	0
	MSM	5,049
	тд	284
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	496
	PrEP_NEW_N_DSD_Age_Sex_v2	
	25-29, Male	1,471
	PrEP_NEW_N_DSD_Age_Sex_v2	225
	30-34, Female	225
	PrEP_NEW_N_DSD_Age_Sex_v2	674
	30-34, Male	674
	PrEP_NEW_N_DSD_Age_Sex_v2	86
	35-39, Female	00



	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	256
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	46
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	123
	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	277
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	82,543
	Age/sex: 10-14 Male	1,852
	Age/sex: 15-19 Male	1,852
PP_PREV_DSD	Age/sex: 20-24 Male	9,294
	Age/sex: 50+ Male	3,015
	Age/sex: 10-14 Female	623
	Age/sex: 15-19 Female	623
	Age/sex: 20-24 Female	3,106
	Age/sex: 50+ Female	1,038
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	4,544
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	13,626
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	4,544
	PP_PREV_N_DSD_Age_Sex_v2	13,626



	30-34, Male	
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	3,106
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	9,294
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	3,106
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	9,294
	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000
	Age/sex: 20-24 Male KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	50,000 n/a
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	120,319
	By key population type: Men who have sex with men who are NOT	53,107



sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	5,096
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	3,530
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs ( Male PWID)	
(Numerator: Number of key	
populations reached with individual	5,804
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	2,782
populations reached with individual	.,. 02
and/or small group level HIV	



	based on evidence and/or meet the	
	minimum standards required)	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,000
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Female, Negative	1,548
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Male, Negative	4,644
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Female, Negative	1,548
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Female, Positive	10
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Male, Negative	4,644
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Male, Positive	21
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Female, Negative	2,167
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Female, Positive	15
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Male, Negative	6,500
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Male, Positive	30
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 40-49, Female, Negative	929
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 40-49, Male, Negative	2,787
	HTS_TST_N_TA_PMTCT_Age_Se x_Result 25-29, Female, Negative	996
	HTS_TST_N_TA_PMTCT_Age_Se x_Result 30-34, Female, Negative	664



HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Negative	6
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Negative	26
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Negative	7
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Negative	27
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Positive	2
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Negative	15
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Negative	60
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Positive	4
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Negative	4
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Male, Negative	19
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Negative	206
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Negative	620
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Negative	206
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Positive	2
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Negative	620



	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Positive	8
	HTS_TST_N_TA_VCT_Age_Sex_	289
	Result 35-39, Female, Negative	200
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Positive	3
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Negative	867
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Positive	9
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	124
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	371
	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	172
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	172
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	138
	Aggregated Age/Sex: Male 15+	138



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34
	HTS_SELF_N_DSD	45,842
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	383
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	755
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	1,157
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	2,261
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	1,297
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	2,494
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	3,855
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	7,485
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	1,369



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	2,649
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	4,081
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	7,951
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	750
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	1,432
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	2,222
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	4,322
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	26
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	72
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	110
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	221
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	27
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female,	66



	Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	108
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	219
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	22
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	63
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	102
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	343
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	15,506
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	30,336
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	257,246
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	6
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	114
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6



	e Delivery Point (Facility) PITC: 20-24, Female, ve	226
Service	e Delivery Point (Facility) PITC: 20-24, Female,	13
	e Delivery Point (Facility) PITC: 20-24, Male, Negative	718
	e Delivery Point (Facility) PITC: 20-24, Male, Positive	38
	e Delivery Point (Facility) PITC: 50+, Female, Negative	38
	e Delivery Point (Facility) PITC: 50+, Female, Positive	0
	e Delivery Point (Facility) PITC: 50+, Male, Negative	30
	e Delivery Point (Facility) PITC: 50+, Male, Positive	0
	e Delivery Point (Community) 15-19, Female, Negative	1,497
	e Delivery Point (Community) 15-19, Female, Positive	53
	e Delivery Point (Community) 15-19, Male, Negative	2,264
	e Delivery Point (Community) 15-19, Male, Positive	79
	e Delivery Point (Community) 20-24, Female, Negative	4,512
	e Delivery Point (Community) 20-24, Female, Positive	173
	e Delivery Point (Community) 20-24, Male, Negative	14,289
	e Delivery Point (Community) 20-24, Male, Positive	549



Service Delivery Point (Community) Other: 50+, Female, Negative756Service Delivery Point (Community) Other: 50+, Female, Positive17Service Delivery Point (Community) Other: 50+, Male, Negative802Service Delivery Point (Community) Other: 50+, Male, Negative57Service Delivery Point (Facility) Index: 15-19, Female, Negative431Service Delivery Point (Facility) Index: 15-19, Female, Negative24Service Delivery Point (Facility) Index: 15-19, Male, Negative647Service Delivery Point (Facility) Index: 15-19, Male, Negative45Service Delivery Point (Facility) Index: 15-19, Male, Negative103Service Delivery Point (Facility) Index: 20-24, Female, Negative103Service Delivery Point (Facility) Index: 20-24, Female, Positive103Service Delivery Point (Facility) Index: 20-24, Male, Negative322Service Delivery Point (Facility) Index: 20-24, Female, Negative322Service Delivery Point (Facility) Index: 20-24, Female, Negative322Service Delivery Point (Facility) Index: 50+, Female, Negative322Service Delivery Point (Facility) Index: 50+, Female, Negative322Service Delivery Point (Facility) Index: 50+, Female, Positive322Service Delivery Point (Facility) Index: 50+, Female, Negative322Service Delivery Point (Facility) Index: 50+, Female, Negative323Service Delivery Point (Facility) Index: 50+, Male, Negative323Service Delivery Point (Facility) Index: 50+, Male, Negative323Service De		
Other: 50+, Female, Positive17Service Delivery Point (Community)802Service Delivery Point (Community)57Other: 50+, Male, Negative57Service Delivery Point (Facility)431Index: 15-19, Female, Negative431Service Delivery Point (Facility)24Index: 15-19, Female, Positive647Service Delivery Point (Facility)647Index: 15-19, Male, Negative647Service Delivery Point (Facility)45Index: 15-19, Male, Positive1,306Service Delivery Point (Facility)1,306Index: 20-24, Female, Negative103Service Delivery Point (Facility)103Index: 20-24, Male, Negative322Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)10Index: 50+, Female, Negative220Service Delivery Point (Facility)10Index: 50+, Female, Positive10Service Delivery Point (Facility)10Index: 50+, Female, Positive223Service Delivery Point (Facility)223Service Delivery Point (Facility)73Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935		756
Other: 50+, Male, Negative802Service Delivery Point (Community) Other: 50+, Male, Positive57Service Delivery Point (Facility) Index: 15-19, Female, Negative431Service Delivery Point (Facility) Index: 15-19, Female, Positive24Service Delivery Point (Facility) Index: 15-19, Male, Negative647Service Delivery Point (Facility) Index: 15-19, Male, Negative647Service Delivery Point (Facility) Index: 15-19, Male, Positive1,306Service Delivery Point (Facility) Index: 20-24, Female, Negative103Service Delivery Point (Facility) Index: 20-24, Male, Negative103Service Delivery Point (Facility) Index: 20-24, Male, Negative322Service Delivery Point (Facility) Index: 20-24, Male, Negative322Service Delivery Point (Facility) Index: 20-24, Male, Negative322Service Delivery Point (Facility) Index: 50+, Female, Negative10Service Delivery Point (Facility) Index: 50+, Female, Negative10Service Delivery Point (Facility) Index: 50+, Male, Negative223Service Delivery Point (Facility) Index: 50+, Male, Negative223Service Delivery Point (Facility) Index: 50+, Male, Positive73Service Delivery Point (Facility) Index: 50+, Male, Positive73		17
Other: 50+, Male, Positive57Service Delivery Point (Facility) Index: 15-19, Female, Negative431Service Delivery Point (Facility) Index: 15-19, Female, Positive24Service Delivery Point (Facility) Index: 15-19, Male, Negative647Service Delivery Point (Facility) Index: 15-19, Male, Negative45Service Delivery Point (Facility) Index: 15-19, Male, Positive1,306Service Delivery Point (Facility) Index: 20-24, Female, Negative103Service Delivery Point (Facility) Index: 20-24, Female, Negative103Service Delivery Point (Facility) Index: 20-24, Male, Negative322Service Delivery Point (Facility) Index: 50+, Female, Negative322Service Delivery Point (Facility) Index: 50+, Female, Negative10Service Delivery Point (Facility) Index: 50+, Female, Negative10Service Delivery Point (Facility) Index: 50+, Male, Negative223Service Delivery Point (Facility) Index: 50+, Male, Negative223Service Delivery Point (Facility) Index: 50+, Male, Positive73Service Delivery Point (Facility) Index: 50+, Male, Positive73		802
Index: 15-19, Female, Negative431Service Delivery Point (Facility)24Index: 15-19, Female, Positive647Service Delivery Point (Facility)647Index: 15-19, Male, Negative647Service Delivery Point (Facility)45Index: 15-19, Male, Positive45Service Delivery Point (Facility)1,306Index: 20-24, Female, Negative1,306Service Delivery Point (Facility)103Index: 20-24, Female, Negative4,107Service Delivery Point (Facility)103Index: 20-24, Male, Negative322Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)10Index: 50+, Female, Negative10Service Delivery Point (Facility)10Index: 50+, Female, Negative223Service Delivery Point (Facility)223Index: 50+, Male, Negative73By Key Population: FSW, Negative13,935		57
Index: 15-19, Female, Positive24Service Delivery Point (Facility)647Index: 15-19, Male, Negative647Service Delivery Point (Facility)45Index: 15-19, Male, Positive45Service Delivery Point (Facility)1,306Index: 20-24, Female, Negative1,306Service Delivery Point (Facility)103Index: 20-24, Female, Positive103Service Delivery Point (Facility)103Index: 20-24, Male, Negative4,107Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)322Index: 50+, Female, Negative10Service Delivery Point (Facility)10Index: 50+, Male, Negative10Service Delivery Point (Facility)10Index: 50+, Male, Negative223Service Delivery Point (Facility)223Index: 50+, Male, Positive73Index: 50+, Male, Positive13,935		431
Index: 15-19, Male, Negative647Service Delivery Point (Facility)45Index: 15-19, Male, Positive45Service Delivery Point (Facility)1,306Index: 20-24, Female, Negative103Service Delivery Point (Facility)103Index: 20-24, Female, Positive103Service Delivery Point (Facility)4,107Index: 20-24, Male, Negative4,107Service Delivery Point (Facility)322Index: 20-24, Male, Negative322Service Delivery Point (Facility)322Index: 50+, Female, Negative200Service Delivery Point (Facility)10Index: 50+, Female, Positive10Service Delivery Point (Facility)10Index: 50+, Male, Negative223Service Delivery Point (Facility)223Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935		24
Index: 15-19, Male, Positive45Service Delivery Point (Facility)1,306Index: 20-24, Female, Negative1,306Service Delivery Point (Facility)103Index: 20-24, Female, Positive103Service Delivery Point (Facility)4,107Index: 20-24, Male, Negative4,107Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)10Index: 50+, Female, Negative10Service Delivery Point (Facility)10Index: 50+, Male, Negative223Service Delivery Point (Facility)123Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935		647
Index: 20-24, Female, Negative1,306Service Delivery Point (Facility)103Index: 20-24, Female, Positive103Service Delivery Point (Facility)4,107Index: 20-24, Male, Negative322Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)322Index: 50-24, Male, Positive220Service Delivery Point (Facility)10Index: 50+, Female, Negative10Service Delivery Point (Facility)10Service Delivery Point (Facility)223Index: 50+, Male, Negative223Service Delivery Point (Facility)73Index: 50+, Male, Positive13,935		45
Index: 20-24, Female, Positive103Service Delivery Point (Facility)4,107Index: 20-24, Male, Negative322Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)220Index: 50+, Female, Negative10Service Delivery Point (Facility)10Index: 50+, Female, Positive10Service Delivery Point (Facility)223Index: 50+, Male, Negative223Service Delivery Point (Facility)23Index: 50+, Male, Negative73By Key Population: FSW, Negative13,935		1,306
Index: 20-24, Male, Negative4,107Service Delivery Point (Facility)322Index: 20-24, Male, Positive322Service Delivery Point (Facility)220Index: 50+, Female, Negative10Service Delivery Point (Facility)10Index: 50+, Female, Positive223Service Delivery Point (Facility)223Index: 50+, Male, Negative73Service Delivery Point (Facility)73Service Delivery Point (Facility)13,935		103
Index: 20-24, Male, Positive322Service Delivery Point (Facility)220Index: 50+, Female, Negative10Service Delivery Point (Facility)10Index: 50+, Female, Positive223Service Delivery Point (Facility)223Index: 50+, Male, Negative73Service Delivery Point (Facility)73Index: 50+, Male, Positive13,935		4,107
Index: 50+, Female, Negative220Service Delivery Point (Facility)10Index: 50+, Female, Positive10Service Delivery Point (Facility)223Index: 50+, Male, Negative223Service Delivery Point (Facility)73Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935	, , , , , , , , , , , , , , , , , , ,	322
Index: 50+, Female, Positive10Service Delivery Point (Facility)223Index: 50+, Male, Negative223Service Delivery Point (Facility)73Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935		220
Index: 50+, Male, Negative223Service Delivery Point (Facility)73Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935	,	10
Index: 50+, Male, Positive73By Key Population: FSW, Negative13,935	, , , , , , , , , , , , , , , , , , ,	223
		73
By Key Population: FSW, Positive 218	By Key Population: FSW, Negative	13,935
	By Key Population: FSW, Positive	218



By Key Population: MSM, Negative	33,018
By Key Population: MSM, Positive	3,085
By Key Population: People in	4 500
orisons and other enclosed settings, Negative	1,506
By Key Population: People in	
risons and other enclosed	17
settings, Positive	
By Key Population: PWID,	47,566
Negative	47,500
By Key Population: PWID, Positive	1,813
By Key Population: TG, Negative	491
By Key Population: TG, Positive	17
Service Delivery Point (Community)	
Index Mod: 15-19, Female,	382
Negative	
Service Delivery Point (Community)	24
Index Mod: 15-19, Female, Positive	24
Service Delivery Point (Community)	563
ndex Mod: 15-19, Male, Negative	505
Service Delivery Point (Community)	51
Index Mod: 15-19, Male, Positive	51
Service Delivery Point (Community)	
Index Mod: 20-24, Female,	1,132
Negative	
Service Delivery Point (Community)	89
ndex Mod: 20-24, Female, Positive	
Service Delivery Point (Community)	3,583
Index Mod: 20-24, Male, Negative	,
Service Delivery Point (Community)	286
ndex Mod: 20-24, Male, Positive	
Service Delivery Point (Community)	184
ndex Mod: 50+, Female, Negative	
Service Delivery Point (Community)	6



Index Mod: 50+, Female, Positive	
Service Delivery Point (Community)	201
ndex Mod: 50+, Male, Negative	201
Service Delivery Point (Community)	33
ndex Mod: 50+, Male, Positive	33
Service Delivery Point (Facility)	2,544
VCT: 15-19, Female, Negative	۷,044
Service Delivery Point (Facility)	84
VCT: 15-19, Female, Positive	04
Service Delivery Point (Facility)	2 000
VCT: 15-19, Male, Negative	3,809
Service Delivery Point (Facility)	100
VCT: 15-19, Male, Positive	132
Service Delivery Point (Facility)	7 005
VCT: 20-24, Female, Negative	7,625
Service Delivery Point (Facility)	050
VCT: 20-24, Female, Positive	259
Service Delivery Point (Facility)	04.400
VCT: 20-24, Male, Negative	24,132
Service Delivery Point (Facility)	222
VCT: 20-24, Male, Positive	822
Service Delivery Point (Facility)	4.074
VCT: 50+, Female, Negative	1,271
Service Delivery Point (Facility)	
VCT: 50+, Female, Positive	39
Service Delivery Point (Facility)	
VCT: 50+, Male, Negative	1,278
Service Delivery Point (Facility)	
VCT: 50+, Male, Positive	52
HTS_TST_N_DSD_Index_Age_Se	
	1,728
x_Result 25-29, Female, Negative	
x_Result 25-29, Female, Negative	
-	134



x_Result 25-29, Male, Negative	
HTS_TST_N_DSD_Index_Age_Se x_Result 25-29, Male, Positive	322
HTS_TST_N_DSD_Index_Age_Se x_Result 30-34, Female, Negative	1,518
HTS_TST_N_DSD_Index_Age_Se x_Result 30-34, Female, Positive	116
HTS_TST_N_DSD_Index_Age_Se x_Result 30-34, Male, Negative	3,901
HTS_TST_N_DSD_Index_Age_Se x_Result 30-34, Male, Positive	297
HTS_TST_N_DSD_Index_Age_Se x_Result 35-39, Female, Negative	867
HTS_TST_N_DSD_Index_Age_Se x_Result 35-39, Female, Positive	60
HTS_TST_N_DSD_Index_Age_Se x_Result 35-39, Male, Negative	1,729
HTS_TST_N_DSD_Index_Age_Se x_Result 35-39, Male, Positive	134
HTS_TST_N_DSD_Index_Age_Se x_Result 40-49, Female, Negative	431
HTS_TST_N_DSD_Index_Age_Se x_Result 40-49, Female, Positive	25
HTS_TST_N_DSD_Index_Age_Se x_Result 40-49, Male, Negative	431
HTS_TST_N_DSD_Index_Age_Se x_Result 40-49, Male, Positive	24
HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Negative	1,508
HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Positive	122
HTS_TST_N_DSD_NdxMod_Age_	3,583



Sex_Result 25-29, Male, Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 25-29, Male, Positive	283
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 30-34, Female,	1,322
Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 30-34, Female,	97
Positive	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 30-34, Male, Negative	3,398
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 30-34, Male, Positive	265
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 35-39, Female,	745
Negative	-
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 35-39, Female,	63
Positive	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 35-39, Male, Negative	1,508
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 35-39, Male, Positive	112
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Female,	382
Negative	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Female,	24
Positive	
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Male, Negative	381
HTS_TST_N_DSD_NdxMod_Age_	
Sex_Result 40-49, Male, Positive	24
HTS_TST_N_DSD_OtPITC_Age_	303
	503



Sex_Result 25-29, Female,       Negative         HTS_TST_N_DSD_OtPITC_Age_       Sex_Result 25-29, Female,       15         Positive       HTS_TST_N_DSD_OtPITC_Age_       Sex_Result 25-29, Male, Negative       718         HTS_TST_N_DSD_OIPITC_Age_       Sex_Result 25-29, Male, Negative       37       37         HTS_TST_N_DSD_OIPITC_Age_       Sex_Result 25-29, Male, Positive       37         HTS_TST_N_DSD_OIPITC_Age_       Sex_Result 30-34, Female,       264         Negative       HTS_TST_N_DSD_OIPITC_Age_       Sex_Result 30-34, Female,       13         Positive       HTS_TST_N_DSD_OIPITC_Age_       680       Sex_Result 30-34, Male, Negative       680         HTS_TST_N_DSD_OIPITC_Age_       Sex_Result 30-34, Male, Negative       Ses		
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Negative718HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Negative37HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive264HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive13Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive7Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive7Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive77	Sex_Result 25-29, Female,	
Sex_Result 25-29, Female, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Negative718HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Negative37HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive264Negative13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative77Negative HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative77	Negative	
PositiveHTS_TST_N_DSD_OIPITC_Age_ Sex_Result 25-29, Male, Negative718HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 25-29, Male, Positive37HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 30-34, Female, Negative264HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 30-34, Female, Positive13Positive13Positive680HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 35-39, Female, Positive7Positive151HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 40-49, Female, Regative77Negative HTS_TST_N_DSD_OIPITC_Age_ Sex_Result 40-49, Female, Result 40-49, Female, Result 40-49, Female,6	HTS_TST_N_DSD_OtPITC_Age_	
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Negative718HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Positive37HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Negative264HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive13Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive7Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 36-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Regative77Negative77Negative6	Sex_Result 25-29, Female,	15
Sex_Result 25-29, Male, Negative718HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Positive37HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive264HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Negative7Positive7HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative77Negative HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative6	Positive	
Sex_Result 25-29, Male, Negative       37         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Positive       37         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female,       264         Negative       13         Positive       13         Positive       680         Sex_Result 30-34, Female,       13         Positive       13         Positive       680         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative       680         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative       35         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,       151         Negative       151       Negative         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,       7         Positive       7       203         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative       303         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative       15         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,       77         Negative       15       15         HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,       77         Negative       6       15	HTS_TST_N_DSD_OtPITC_Age_	710
Sex_Result 25-29, Male, Positive37HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Negative264HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Negative151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, HTS_TST_N_DSD_OTPITC_Age_ 	Sex_Result 25-29, Male, Negative	/10
Sex_Result 25-29, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Female,         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Female,         Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Female,         Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Female,         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Female,         Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,         Result 40-49, Female,         6 <td>HTS_TST_N_DSD_OtPITC_Age_</td> <td>07</td>	HTS_TST_N_DSD_OtPITC_Age_	07
Sex_Result 30-34, Female, Negative264HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive13Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 25-29, Male, Positive	37
NegativeHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female,13Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	HTS_TST_N_DSD_OtPITC_Age_	
TS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female,13Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 30-34, Female,	264
Sex_Result 30-34, Female,13Positive13HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,76	Negative	
PositiveHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,303Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative6	HTS_TST_N_DSD_OtPITC_Age_	
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive7HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Sex_Result 40-49, Female,77Negative HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Sex_Result 40-49, Female,6	Sex_Result 30-34, Female,	13
Sex_Result 30-34, Male, Negative680HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,303Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative6	Positive	
Sex_Result 30-34, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 30-34, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Female,         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Female,         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Female,         Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Negative         MTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,         Result 40-49, Female,         6	HTS_TST_N_DSD_OtPITC_Age_	000
Sex_Result 30-34, Male, Positive35HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive100HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 30-34, Male, Negative	680
Sex_Result 30-34, Male, PositiveHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive100HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative17HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	HTS_TST_N_DSD_OtPITC_Age_	
Sex_Result 35-39, Female,151Negative151HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive7HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303Sex_Result 35-39, Male, Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 30-34, Male, Positive	35
NegativeHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive7HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative77HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	HTS_TST_N_DSD_OtPITC_Age_	
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female,7Positive1HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,76	Sex_Result 35-39, Female,	151
Sex_Result 35-39, Female, Positive7Positive1000HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative17HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Negative	
PositiveHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	HTS_TST_N_DSD_OtPITC_Age_	
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 35-39, Female,	7
Sex_Result 35-39, Male, Negative303HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77NegativeHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Positive	
Sex_Result 35-39, Male, Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 35-39, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,         6	HTS_TST_N_DSD_OtPITC_Age_	000
Sex_Result 35-39, Male, Positive15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,77Negative15HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 35-39, Male, Negative	303
Sex_Result 35-39, Male, Positive         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,       77         Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,       6	HTS_TST_N_DSD_OtPITC_Age_	45
Sex_Result 40-49, Female,77NegativeHTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female,6	Sex_Result 35-39, Male, Positive	15
Negative         HTS_TST_N_DSD_OtPITC_Age_         Sex_Result 40-49, Female,       6	HTS_TST_N_DSD_OtPITC_Age_	
HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, 6	Sex_Result 40-49, Female,	77
Sex_Result 40-49, Female, 6	Negative	
	HTS_TST_N_DSD_OtPITC_Age_	
Positive	Sex_Result 40-49, Female,	6
	 Positive	



HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Negative	77
HTS_TST_N_DSD_OtPITC_Age_	6
Sex_Result 40-49, Male, Positive	
HTS_TST_N_DSD_OtrMod_Age_	C 024
Sex_Result 25-29, Female, Negative	6,024
_	
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female,	230
Positive	230
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Negative	14,316
HTS_TST_N_DSD_OtrMod_Age_	550
Sex_Result 25-29, Male, Positive	550
HTS_TST_N_DSD_OtrMod_Age_	
Sex_Result 30-34, Female,	5,251
Negative	
HTS_TST_N_DSD_OtrMod_Age_	
Sex_Result 30-34, Female,	198
Positive	
HTS_TST_N_DSD_OtrMod_Age_	10 544
Sex_Result 30-34, Male, Negative	13,544
HTS_TST_N_DSD_OtrMod_Age_	526
Sex_Result 30-34, Male, Positive	520
HTS_TST_N_DSD_OtrMod_Age_	
Sex_Result 35-39, Female,	3,001
Negative	
HTS_TST_N_DSD_OtrMod_Age_	
Sex_Result 35-39, Female,	124
Positive	
HTS_TST_N_DSD_OtrMod_Age_	6,039
Sex_Result 35-39, Male, Negative	0,000
HTS_TST_N_DSD_OtrMod_Age_	231
Sex_Result 35-39, Male, Positive	231



HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female,	1,508
Negative HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female, Positive	54
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Negative	1,544
HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Positive	55
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	10,163
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	346
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	24,132
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	821
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	8,892
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	295
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	22,869
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	765
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	5,079
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	169
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	10,163
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	346



	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	2,544
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	84
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	2,544
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	84
	TB_PREV_DSD TB_PREV_DSD	85 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,993
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,698
	By Age/Sex (Denominator): <15, Female	68
	By Age/Sex (Denominator): <15, Male	68
	By Age/Sex (Denominator): 15+, Female	1,587
	By Age/Sex (Denominator): 15+, Male	2,975
	By Age/Sex (Numerator): <15, Female	61



	By Age/Sex (Numerator): <15, Male	61
	By Age/Sex (Numerator): 15+, Female	1,352
	By Age/Sex (Numerator): 15+, Male	2,519
	TB_PREV_TA TB_PREV_TA	n/a
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	0
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	0
	By Age/Sex (Denominator): <15, Female	0
	By Age/Sex (Denominator): <15, Male	0
	By Age/Sex (Denominator): 15+, Female	0
	By Age/Sex (Denominator): 15+, Male	0
	By Age/Sex (Numerator): <15, Female	0
	By Age/Sex (Numerator): <15, Male	0



	By Age/Sex (Numerator): 15+, Female	0
	By Age/Sex (Numerator): 15+, Male	0
	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	1 %
	Number of ART patients who were started on TB treatment during the reporting period.	997
	Number of ART patients who were screened for TB at least once during the reporting period	67,989
	Numerator: By Aggregated Age/Sex: <15, Female	5
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	5
	Numerator: By Aggregated Age/Sex: 15+, Female	333
	Numerator: By Aggregated Age/Sex: 15+, Male	654
	Denominator: By Aggregated Age/Sex: <15, Female	1,059
	Denominator: By Aggregated Age/Sex: <15, Male	1,059
	Denominator: By Aggregated Age/Sex:15+, Female	23,055
	Denominator: By Aggregated Age/Sex:15+, Male	42,816
ТХ_ТВ_ТА	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	n/a
	Number of ART patients who were started on TB treatment during the	0



	reporting period.	
	Number of ART patients who were screened for TB at least once during the reporting period	0
	Numerator: By Aggregated Age/Sex: <15, Female	0
	Numerator: By Aggregated Age/Sex: <15, Male	0
	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_CURR_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	0
	Denominator: By Aggregated Age/Sex: <15, Female	0
	Denominator: By Aggregated Age/Sex: <15, Male	0
	Denominator: By Aggregated Age/Sex: 15+, Female	0
	Denominator: By Aggregated Age/Sex: 15+, Male	0
	Number of adults and children receiving antiretroviral therapy (ART)	75,739
	Age/Sex: 15-19 Male	2,213
	Age/Sex: 15-19 Female	1,472
	Age/Sex: <1	0
	Age/Sex: <1-9	927
	Age/Sex: 10-14 Male	446
	Age/Sex: 10-14 Female	465
	Age/Sex: 20-24 Male	13,265
	Age/Sex: 50+ Male	728
	Age/Sex: 20-24 Female	6,633
	Age/Sex: 50+ Female	740



TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive6,639TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive12,550TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive5,914TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive11,843TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive11,843TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive2,964TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive5,950TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Age/Sex: 15-19 Female0Sum of Age/Sex disaggregations0Age/Sex: 1-90			
TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive12,550TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive5,914TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive11,843TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive2,964TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive5,950TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Sum of Age/Sex disaggregations0Age/Sex: <1		-	6,639
TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive5,914TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive11,843TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive2,964TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive5,950TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Age/Sex: 15-19 Female0Sum of Age/Sex disaggregations0Age/Sex: <1		TX_CURR_N_DSD_Age_Sex_HIV	12,550
TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive11,843TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive2,964TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive5,950TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Age/Sex: 15-19 Female0Sum of Age/Sex disaggregations0Age/Sex: <1		TX_CURR_N_DSD_Age_Sex_HIV	5,914
TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive2,964TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive5,950TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Sum of Age/Sex disaggregations0Age/Sex: <1		TX_CURR_N_DSD_Age_Sex_HIV	11,843
Status 35-39, Male, Positive5,950TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Age/Sex: 15-19 Female0Sum of Age/Sex disaggregations0Age/Sex: <1		TX_CURR_N_DSD_Age_Sex_HIV	2,964
Status 40-49, Female, Positive1,484TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive1,506Number of adults and children receiving antiretroviral therapy (ART)152Age/Sex: 15-19 Male0Age/Sex: 15-19 Female0Sum of Age/Sex disaggregations0Age/Sex: <1		_	5,950
Status 40-49, Male, Positive       1,506         Number of adults and children       receiving antiretroviral therapy         receiving antiretroviral therapy       152         (ART)       Age/Sex: 15-19 Male       0         Age/Sex: 15-19 Female       0         Sum of Age/Sex disaggregations       0         Age/Sex: <1		-	1,484
receiving antiretroviral therapy 152 (ART) Age/Sex: 15-19 Male 0 Age/Sex: 15-19 Female 0 Sum of Age/Sex disaggregations 0 Age/Sex: <1 0			1,506
Age/Sex: 15-19 Female0Sum of Age/Sex disaggregations0Age/Sex: <1		receiving antiretroviral therapy	152
Sum of Age/Sex disaggregations0Age/Sex: <1		Age/Sex: 15-19 Male	0
Age/Sex: <1 0		Age/Sex: 15-19 Female	0
	TX_CURR_TA	Sum of Age/Sex disaggregations	0
Age/Sex: 1-9 0		Age/Sex: <1	0
		Age/Sex: 1-9	0
TX_CURR_TA Age/Sex: 10-14 Male 0		Age/Sex: 10-14 Male	0
Age/Sex: 10-14 Female 0		Age/Sex: 10-14 Female	0
Age/Sex: 20-24 Male 0		Age/Sex: 20-24 Male	0
Age/Sex: 50+ Male 0		Age/Sex: 50+ Male	0
Age/Sex: 20-24 Female 0		Age/Sex: 20-24 Female	0
Age/Sex: 50+ Female 0		Age/Sex: 50+ Female	0
TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive		-	4
		TX_CURR_N_TA_Age_Sex_HIVSt	14



	atus 25-29, Male, Positive	
	TX_CURR_N_TA_Age_Sex_HIVSt	16
	atus 30-34, Female, Positive	10
	TX_CURR_N_TA_Age_Sex_HIVSt	31
	atus 30-34, Male, Positive	
	TX_CURR_N_TA_Age_Sex_HIVSt	22
	atus 35-39, Female, Positive	
	TX_CURR_N_TA_Age_Sex_HIVSt	48
	atus 35-39, Male, Positive	
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	10
	TX_CURR_N_TA_Age_Sex_HIVSt	7
	atus 40-49, Male, Positive Number of adults and children	
	newly enrolled on antiretroviral	13,330
	therapy (ART)	10,000
	By Age/Sex: <1	0
	By Age/Sex: 1-9	56
	By Age/Sex: 10-14 Male	14
	By Age/Sex: 15-19 Male	402
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,382
	By Age/Sex: 50+ Male	129
	By Age/Sex: 10-14 Female	22
	By Age/Sex: 15-19 Female	266
	By Age/Sex: 20-24 Female	1,186
	By Age/Sex: 50+ Female	135
	TX_NEW_N_DSD_Age_Sex_HIVS	4.400
	tatus 25-29, Female, Positive	1,189
	TX_NEW_N_DSD_Age_Sex_HIVS	2,247
	tatus 25-29, Male, Positive	۷,۷41
	TX_NEW_N_DSD_Age_Sex_HIVS	1,063
	tatus 30-34, Female, Positive	· · · · · · · · · · · · · · · · · · ·
	TX_NEW_N_DSD_Age_Sex_HIVS	2,117



	tatus 30-34, Male, Positive	
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	528
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	1,062
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	266
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	266
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	32
	By Age/Sex: <1	0
TX_NEW_TA	By Age/Sex: 1-9	0
	By Age/Sex: 10-14 Male	0
	By Age/Sex: 15-19 Male	0
	By Age/Sex: 20-24 Male	0
	By Age/Sex: 50+ Male	0
	By Age/Sex: 10-14 Female	0
	By Age/Sex: 15-19 Female	0
	By Age/Sex: 20-24 Female	0
	By Age/Sex: 50+ Female	0
	Sum of Age/Sex disaggregates	0
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	5
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Male, Positive	8
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	4
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	9
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Female, Positive	1



	TX_NEW_N_TA_Age_Sex_HIVSta	5
	tus 35-39, Male, Positive TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Female, Positive	0
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Male, Positive	0
	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	73,378
	Denominator: Indication: Routine	73,378
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,134
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	46,246
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,134
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,864
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART	152



		]
	patients with a viral load result	
	documented in the patient medical	
	record and /or laboratory records	
	in the past 12 months.	
	Denominator: Indication: Routine	152
	Denominator: Aggregate Age/Sex	0
	by Indication: <15 Female Routine	0
	Denominator: Aggregate Age/Sex	2
	by Indication: <15 Male Routine	0
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Female Routine	52
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Male Routine	100
	TX_RET_DSD Percent of adults	
	and children known to be alive and	
	on treatment 12 months after	90 %
	initiation of antiretroviral therapy	
	Number of adults and children who	
	are still alive and on treatment at	5,285
TX_RET_DSD	12 months after initiating ART	
	Total number of adults and children	
	who initiated ART in the 12 months	
	prior to the beginning of the	
	reporting period, including those	5,872
	who have died, those who have	
	stopped ART, and those lost to	
	follow-up	
	Aggregated Age/Sex: <15 Male	
	(Numerator: Number of adults and	
	children who are still alive and on	1,809
	treatment at 12 months after	
	initiating ART)	
	Aggregated Age/Sex: 15+ Male	
	(Numerator: Number of adults and	3,366
	children who are still alive and on	



treatment at 12 months after initiating ART)	
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	61
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,016
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,735
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69



	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	52
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	0



initiating ART)	
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	0



those who have stopped ART, and	
those lost to follow-up)	



# **Partners and Implementing Mechanisms**

#### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9972	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
9976	Ministry of Health, Vietnam	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,350,288
9977	National Institute for Hygiene and Epidemiology	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	305,000
9998	Pasteur Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	380,000



		1	k.		,
			U.S. Department of Health and		
	Harvard Medical				
10000	School of AIDS	Linixoroity	Human		706 951
10000	Initiative in	University	Services/Centers	GHP-State	726,851
	Vietnam		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Vietnam	Implementing	Human		
10118	Administration for	Agency		GHP-State	260,000
	Medical Sciences		for Disease		
			Control and		
			Prevention		
			U.S. Department		
	Clinical and		of Health and		
	Laboratory		Human		
10831	Standards	NGO	Services/Centers		
	Institute		for Disease		
	Institute		Control and		
			Prevention		
			U.S. Department		
			of Health and		
	American Society		Human		
10832	of Clinical	NGO	Services/Centers	GHP-State	400,000
	Pathology		for Disease		
			Control and		
			Prevention		
			U.S. Department		
11000	U.S. Department	Other USG	of State/Bureau of		
11609	of State	Agency	East Asian and	GHP-State	30,000
			Pacific Affairs		
100.11	Vietnam Nurses'	Implementing	U.S. Department		
12341	Association	Agency	of Defense	GHP-State	309,980
	National	Host Country	U.S. Department		
13007	Tuberculosis	Government	of Health and	GHP-State	270,000
L				l	I]



	Program	Agency	Human		
		, geney	Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13147	New York AIDS	Other USG	Services/Centers		
	Institute	Agency	for Disease		
			Control and		
			Prevention		
	KNCV		U.S. Agency for		
13234	Tuberculosis	NGO	International	GHP-State	447,000
	Foundation		Development		,
			U.S. Department		
			of Health and		
			Human		
13779	World Health	Multi-lateral	Services/Centers	GHP-State	100,000
	Organization	Agency	for Disease		
			Control and		
			Prevention		
	The Center for				
	Community		U.S. Agency for		
14156	Health Research	NGO	International		
	and Development		Development		
			U.S. Department		
			of Health and		
	University of		Human		
14326	California at San	University	Services/Centers	GHP-State	150,000
	Francisco		for Disease		
			Control and		
			Prevention		
			U.S. Department		
14336	Hanoi Medical	University	of Health and	GHP-State	454,000
	University		Human		



		1	1	1	
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
16803	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	1,892,261
17371	Abt Associates	Private Contractor	U.S. Agency for International Development		
18149	Center for Community Health Promotion	NGO	U.S. Department of Defense		
18172	FHI 360	NGO	U.S. Agency for International Development	GHP-State	4,058,871
	Center for		U.S. Agency for		
18173	Promotion of	NGO	International	GHP-State	490,540
	Quality of Life		Development		
	Global Health		U.S. Agency for		
18194	Supply Chain Program	Private Contractor	International Development	GHP-State	466,581
		Host Country	U.S. Department of Health and Human		
18271	Department of Health	Government Agency	Services/Centers for Disease Control and Prevention	GHP-State	1,428,187
18541	TBD	ТВD	Redacted	Redacted	Redacted
18616	CENTER FOR COMMUNITY HEALTH RESEARCH AND	NGO	U.S. Agency for International Development	GHP-State	939,200



	DEVELOPMENT				
			U.S. Department		
			of Health and		
	CENTRE FOR		Human		
	SUPPORTING		Services/Substan		
18618		NGO		GHP-State	254,000
			ce Abuse and		
			Mental Health		
	INITIATIVES		Services		
			Administration		
			U.S. Department		
			of Health and		
	University of		Human		
18619	California at Los	University	Services/Substan	GHP-State	416,000
	Angeles	,	ce Abuse and		
	Ũ		Mental Health		
			Services		
			Administration		
			U.S. Department		
			of Health and		
			Human		
18620	FHI 360	NGO	Services/Centers		
			for Disease		
			Control and		
			Prevention		
70416	[Diacabaldar]	ТВД	U.S. Department		
70410	[Placeholder]		of Defense		
			U.S. Department		
70417	[Placeholder]	TBD	of Defense		
			U.S. Department		
70418			of Health and		
			Human		
	[Placeholder]	твр	Services/Centers		
			for Disease		
			Control and		
			Prevention		
70419	[Placeholder]	TBD	U.S. Department		



			of Health and
			Human
			Services/Centers
			for Disease
			Control and
			Prevention
			U.S. Department
			of Health and
			Human
70420	[Placeholder]	твр	Services/Centers
			for Disease
			Control and
			Prevention
			U.S. Department
			of Health and
			Human
70421	[Placeholder]	твр	Services/Centers
	_		for Disease
			Control and
			Prevention
			U.S. Department
			of Health and
			Human
70422	[Placeholder]	твр	Services/Centers
	_		for Disease
			Control and
			Prevention
			U.S. Department
			of Health and
			Human
70423	[Placeholder]	твр	Services/Centers
			for Disease
			Control and
			Prevention
			U.S. Department
70424	[Placeholder]	TBD	of Health and



		1			]
			Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
70425	[Placeholder]	TBD	Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
70426	[Placeholder]	твр	Services/Centers		
			for Disease		
			Control and		
			Prevention		
70427	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
			of Health and		
			Human		
70428	[Placeholder]	TBD	Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Agency for		
70429	[Placeholder]	TBD	International		
			Development		
			U.S. Department		
			of Health and		
70420	[Dloopholdor]	трр	Human		
70430	[Placeholder]	TBD	Services/Centers		
			for Disease		
			Control and		



			Prevention	
70431	[Placeholder]	TBD	U.S. Agency for International Development	
70520	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator	



# Implementing Mechanism(s)

## **Implementing Mechanism Details**

Mechanism ID: 9972	Mechanism Name: APHL LAB		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Association of Public	Health Laboratories		
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A	A		
G2G: No	Managing Agency:		
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source	Funding Amount		

### Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		boratories
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
	TIVIB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

## Implementing Mechanism Details

Mechanism ID: 9976	Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Vietnam		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 3,350,288	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 845,802	Applied Pipeline Amount: 845,802		
Total All Funding Sources and Applied Pipeline Amount: 4,196,090			
Funding Source	Funding Amount		
GHP-State	3,350,288		



## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID: 9976			
Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC)			
Prime Partner Name:	Ministry of Health, Vietnam		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	224,487	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	782,172
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	891,023
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,452,606
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Indicator Number	Label	2019
	Number of individuals who have been newly enrolled on	
PrEP_NEW_DSD	oral antiretroviral pre-exposure prophylaxis (PrEP) in	560
	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	14
PrEP_NEW_DSD	Male 20-24	146
PrEP_NEW_DSD	Male 50+	0
PrEP_NEW_DSD	Female 15-19	6
PrEP_NEW_DSD	Female 20-24	50
PrEP_NEW_DSD	Female 50+	0
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	504
PrEP_NEW_DSD	TG	28
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	50
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	146
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	22
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	70
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	28
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	28
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,708
PP_PREV_DSD	Age/sex: 10-14 Male	514
PP_PREV_DSD	Age/sex: 15-19 Male	514
PP_PREV_DSD	Age/sex: 20-24 Male	2,558
PP_PREV_DSD	Age/sex: 50+ Male	817
PP_PREV_DSD	Age/sex: 10-14 Female	178
PP_PREV_DSD	Age/sex: 15-19 Female	178



	h	
PP_PREV_DSD	Age/sex: 20-24 Female	852
PP_PREV_DSD	Age/sex: 50+ Female	287
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,898
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,249
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,746
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,249
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,746
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	852
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,558
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	852
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,558
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	49,860
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,642
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,309
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23,896
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence	1,013



	and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	99,375
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	157
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	496
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	264
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	396



HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	786
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	2,488
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	133
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	142
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	560
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,759
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	130



HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	48
HTC_TST_DSD	By Key Population: FSW, Negative	5,386
HTC_TST_DSD	By Key Population: FSW, Positive	83
HTC_TST_DSD	By Key Population: MSM, Negative	12,760
HTC_TST_DSD	By Key Population: MSM, Positive	1,194
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	562
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	6
HTC_TST_DSD	By Key Population: PWID, Negative	18,378
HTC_TST_DSD	By Key Population: PWID, Positive	702
HTC_TST_DSD	By Key Population: TG, Negative	194
HTC_TST_DSD	By Key Population: TG, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	89
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	134
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	269
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	847

Page 55 of 227

FACTS Info v3.8.24.1



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,328
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,992
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,987
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	12,618
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	382
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	666
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	666
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	20



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	742
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,760
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	130
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	648
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,675
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	123
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	373
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	743
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	182
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	182
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	354



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	847
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	309
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	806
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	354
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	210
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	9



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	496
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	183
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	470
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	104
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	210
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	1,050
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	2,488



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	919
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	2,363
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	521
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,050
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	264
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	264
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	5,314
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	12,618
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	382



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4,651
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	11,955
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	354
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,654
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5,314
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,328
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,328
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	40
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,621
TX_CURR_DSD	Age/Sex: 15-19 Male	775
TX_CURR_DSD	Age/Sex: 15-19 Female	516
TX_CURR_DSD	Sum of age/sex disaggregates	1,291
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	416
TX_CURR_DSD	Age/Sex: 10-14 Male	200
TX_CURR_DSD	Age/Sex: 10-14 Female	209
TX_CURR_DSD	Age/Sex: 20-24 Male	4,641

Page 61 of 227

FACTS Info v3.8.24.1



TX_CURR_DSD	Age/Sex: 50+ Male	251
TX_CURR_DSD	Age/Sex: 20-24 Female	2,323
TX_CURR_DSD	Age/Sex: 50+ Female	259
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,323
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	4,386
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,065
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4,129
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,031
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,065
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	516
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	516
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,322
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	23
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	193
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,134
TX_NEW_DSD	By Age/Sex: 50+ Male	58
TX_NEW_DSD	By Age/Sex: 10-14 Female	7
TX_NEW_DSD	By Age/Sex: 15-19 Female	129
TX_NEW_DSD	By Age/Sex: 20-24 Female	562
TX_NEW_DSD	By Age/Sex: 50+ Female	64
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,152
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	561



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,066
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	505
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,002
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	250
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	505
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	129
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	129
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	25,064
TX_PVLS_DSD	Denominator: Indication: Routine	25,064
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	389
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,789
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	389
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,497
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,978
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,197
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	674



<b>F</b>		I
	adults and children who are still alive and on treatment	
	at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_DSD	adults and children who are still alive and on treatment	1,252
	at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number	
TX_RET_DSD	of adults and children who are still alive and on	28
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_DSD	of adults and children who are still alive and on	24
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	749
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	1,391
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	32
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	25
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	9,941
	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	83
HTS_SELF_DSD	Female, Directly-Assisted	03
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	170



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	252
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	489
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	283
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	537
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	833
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,619
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	302
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	575
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	886
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,722
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	168
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	308
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	486
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	935
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	13



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	155
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,335
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	6,606
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,494
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	24
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	24
		•



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	595
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,115
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	22
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	22
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	505
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	945
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	318
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	23,964
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	107
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	209
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	374
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	374
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	8,126
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	15,090

# Implementing Mechanism Details

Mechanism ID: 9977	Mechanism Name: NIHE Follow on		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: National Institute for Hygiene and Epidemiology			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: Yes	Managing Agency: HHS/CDC		

Total All Funding Sources: 305,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 305,000			
Funding Source	Funding Amount		
GHP-State	305,000		



# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:			
	NIHE Follow on		
Prime Partner Name:	National Institute for Hygiene and Epidemiology		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	40,500	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	184,500	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	80,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

## Implementing Mechanism Details

Mechanism ID: 9998	Mechanism Name: PI	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Pasteur Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 380,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 380,000		
Funding Source	Funding Amount	
GHP-State	380,000	

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name:	PI	
Prime Partner Name:	Pasteur Institute	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	28,800
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	351,200
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

## Implementing Mechanism Details

Mechanism ID: 10000	Mechanism Name: HAIVN	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Harvard Medical School of AIDS Initiative in Vietnam		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 726,851	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 726,851		
Funding Source	Funding Amount	
GHP-State	726,851	

Approved



### Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	Mechanism ID: 10000		
Mechanism Name:	HAIVN		
Prime Partner Name:	Harvard Medical School of AIDS Initiative in Vietnam		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	726,851
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Indicator Number	Label	2019
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0
TX_CURR_DSD	Age/Sex: 15-19 Male	0
TX_CURR_DSD	Age/Sex: 15-19 Female	0
TX_CURR_DSD	Sum of age/sex disaggregates	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	0
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	17,472
TX_CURR_TA	Age/Sex: 15-19 Male	496
TX_CURR_TA	Age/Sex: 15-19 Female	331



TX_CURR_TA	Sum of Age/Sex disaggregations	827
TX_CURR_TA	Age/Sex: <1	0
TX_CURR_TA	Age/Sex: 1-9	452
TX_CURR_TA	Age/Sex: 10-14 Male	225
TX_CURR_TA	Age/Sex: 10-14 Female	226
TX_CURR_TA	Age/Sex: 20-24 Male	2,982
TX_CURR_TA	Age/Sex: 50+ Male	169
TX_CURR_TA	Age/Sex: 20-24 Female	1,489
TX_CURR_TA	Age/Sex: 50+ Female	167
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,489
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2,817
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,326
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,653
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	662
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,326
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	331
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	331
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	0



TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	0
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,716
TX_NEW_TA	By Age/Sex: <1	0
TX_NEW_TA	By Age/Sex: 1-9	25
TX_NEW_TA	By Age/Sex: 10-14 Male	9
TX_NEW_TA	By Age/Sex: 15-19 Male	112
TX_NEW_TA	By Age/Sex: 20-24 Male	661
TX_NEW_TA	By Age/Sex: 50+ Male	34
TX_NEW_TA	By Age/Sex: 10-14 Female	11
TX_NEW_TA	By Age/Sex: 15-19 Female	77
TX_NEW_TA	By Age/Sex: 20-24 Female	329
TX_NEW_TA	By Age/Sex: 50+ Female	36
TX_NEW_TA	Sum of Age/Sex disaggregates	1,269



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	329
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	623
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	293
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	585
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	145
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	293
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	77
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	77
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	0
TX_PVLS_DSD	Denominator: Indication: Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	0
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	16,610
TX_PVLS_TA	Denominator: Indication: Routine	16,610
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	256



TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	256
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,631
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,467
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	0



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,551
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,725
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	522
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	973
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	583
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,081



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	0
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	0
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	0
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,156
TB_PREV_TA	The number of ART patients who were newly started on	1,361



TB preventive therapy (including those who newly		
	started on TB preventive therapy in this reporting period	
	and those who started in the previous reporting period	
	but had not been reported as they did not fulfill the minimum requirements for the previous reporting	
	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	21
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	21
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	461
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	858
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	19
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	19
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	390
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	728
	Number of ART patients who were started on TB	0
TX_TB_DSD	treatment during the reporting period.	0
TX_TB_DSD	Number of ART patients who were screened for TB at	0
TX_TB_D3D	least once during the reporting period	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	0
TY TO TA	Number of ART patients who were started on TB	224
TX_TB_TA	treatment during the reporting period.	234
TX_TB_TA	Number of ART patients who were screened for TB at	15,730
	least once during the reporting period	15,750
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	80
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	154
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	245



TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	245
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	5,334
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	9,906

# Implementing Mechanism Details

Mechanism ID: 10118	Mechanism Name: Department of Medical Administration	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Vietnam Administration for M	edical Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 260,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 260,000		
Funding Source	Funding Amount	
GHP-State	260,000	

### Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	10118	
Mechanism Name:	Department of Medical Administration	
Prime Partner Name:	Vietnam Administration for Medical Sciences	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	60,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 10831	Mechanism Name: CLSI LAB	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Clinical and Laboratory Standards Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount



# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	10831	
Mechanism Name:		
Prime Partner Name:	Clinical and Laboratory Standards Institute	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 10832	Mechanism Name: ASCP LAB	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: American Society of Clinical Pa	athology	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 400,000		
Funding Source	Funding Amount	
GHP-State	400,000	

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	400,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 11609	Mechanism Name: Ambassador"s Fund for HIV/AIDS Public Diplomacy	
Funding Agency: State/EAP	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of State		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 30,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 30,000		
Funding Source	Funding Amount	
GHP-State	30,000	



#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	11609		
Mechanism Name: Ambassador''s Fund for HIV/AIDS Public Diplomacy			
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	30,000	
Strategic Area	Budget Code	Planned Amount	



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 12341	Mechanism Name: VNA	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: Vietnam Nurses' Association		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: DOD	
Total All Funding Sources: 309,980	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 525,098		
Total All Funding Sources and Applied Pipeline Amount: 835,078		
Funding Source	Funding Amount	
GHP-State	309,980	

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	38,794
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	55,864
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	7,448
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	40,346
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	45,311
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	110,176
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	12,041
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000
PP_PREV_TA	Age/sex: 20-24 Male	50,000
PP_PREV_TA	Sum of Age/Sex disaggregates	50,000
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,000
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,548
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,644
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	1,548
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	10



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,644
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,167
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	6,500
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	30
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	929
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,787
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	996
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	664
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	27
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	15



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	60
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	19
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	206
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	620
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	206
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	620
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	289
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	867
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	124
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	371



TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	172
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	172
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	138
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	138
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	205
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	6
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	21
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	16
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	46
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	18
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	52
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	12
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	34



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	152
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	14
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	16
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	31
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	22
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	48
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	10
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	7
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	5
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	32



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	5
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	8
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	9
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	5
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	205
TX_PVLS_DSD	Denominator: Indication: Routine	205
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	153
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	52
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	152
TX_PVLS_TA	Denominator: Indication: Routine	152
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	52
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	100

# Implementing Mechanism Details

Mechanism ID: 13007	Mechanism Name: NTP Follow on	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreemen		
Prime Partner Name: National Tuberculosis Program		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: Yes	Managing Agency: HHS/CDC			
otal All Funding Sources: 270,000 Total Mechanism Pipeline: N/A				
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 270,000				
Funding Source	Funding Amount			
GHP-State	270,000			

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	70,200
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	199,800
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 13147	Mechanism Name: HEATHQUAL			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: New York AIDS Institute				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
2G: No Managing Agency:				
Total All Funding Sources: 0 Total Mechanism Pipeline: N/A				
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 0				
Funding Source Funding Amount				

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Budget Code Information**

Mechanism ID: 13147



Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 13234	Mechanism Name: Challenge TB	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: KNCV Tuberculosis Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 447,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 447,000			
Funding Source Funding Amount			
GHP-State	447,000		

#### Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	Mechanism ID: 13234		
Mechanism Name:	Challenge TB		
Prime Partner Name:	KNCV Tuberculosis Foundation		
Strategic Area	Budget Code	Planned Amount	
Care	HBHC	0	
Strategic Area	Budget Code	Planned Amount	
Care	НКІД	0	
Strategic Area	Budget Code	Planned Amount	
Care	НУТВ	447,000	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	



Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMBL	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMIN	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVAB	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVCT	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	МТСТ	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	0
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	0
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	0
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,723
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	2,027



and those who started in the previous reporting period		
but had not been reported as they did not fulfill the		
By Age/Sex (Denominator): <15, Female	29	
By Age/Sex (Denominator): <15, Male	29	
By Age/Sex (Denominator): 15+, Female	684	
By Age/Sex (Denominator): 15+, Male	1,285	
By Age/Sex (Numerator): <15, Female	26	
By Age/Sex (Numerator): <15, Male	26	
By Age/Sex (Numerator): 15+, Female	583	
By Age/Sex (Numerator): 15+, Male	1,088	
Number of ART patients who were started on TB treatment during the reporting period.	0	
Number of ART patients who were screened for TB at least once during the reporting period	0	
Numerator: By Aggregated Age/Sex: <15, Male	0	
Numerator: By Aggregated Age/Sex: 15+, Female	0	
Numerator: By Aggregated Age/Sex: 15+, Male	0	
Denominator: By Aggregated Age/Sex: <15, Female	0	
Denominator: By Aggregated Age/Sex: <15, Male	0	
	0	
	0	
Number of ART patients who were started on TB treatment during the reporting period.	431	
Number of ART patients who were screened for TB at least once during the reporting period	18,420	
Numerator: By Aggregated Age/Sex: <15, Female	4	
Numerator: By Aggregated Age/Sex: <15, Male	4	
Numerator: By Aggregated Age/Sex: 15+, Female	144	
	279	
	288	
	288	
	but had not been reported as they did not fulfill the minimum requirements for the previous reporting period). By Age/Sex (Denominator): <15, Female By Age/Sex (Denominator): 15+, Female By Age/Sex (Denominator): 15+, Female By Age/Sex (Denominator): 15+, Male By Age/Sex (Numerator): <15, Female By Age/Sex (Numerator): <15, Male By Age/Sex (Numerator): <15, Male By Age/Sex (Numerator): 15+, Female By Age/Sex (Numerator): 15+, Female By Age/Sex (Numerator): 15+, Female By Age/Sex (Numerator): 15+, Male Number of ART patients who were started on TB treatment during the reporting period. Number of ART patients who were screened for TB at least once during the reporting period Numerator: By Aggregated Age/Sex: <15, Male Denominator: By Aggregated Age/Sex: 15+, Female Denominator: By Aggregated Age/Sex: <15, Female Denominator: By Aggregated Age/Sex: <15, Female Denominator: By Aggregated Age/Sex: <15, Male Denominator: By Aggregated Age/Sex: <15, Male Number of ART patients who were started on TB treatment during the reporting period. Number of ART patients who were screened for TB at least once during the reporting period. Number of ART patients who were screened for TB at least once during the reporting period. Number of ART patients who were screened for TB at least once during the reporting period.	



TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	6,248
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	11,596

### Implementing Mechanism Details

Mechanism ID: 13779	Mechanism Name: WHO	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 100,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 38,000		
Total All Funding Sources and Applied Pipeline Amount: 138,000		
Funding Source Funding Amount		
GHP-State	100,000	

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	100,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 14156	Mechanism Name: Strengthen In-Country Strategic Information Capacity for Sustainable HIV Response	
Funding Agency: USAID Procurement Type: Contract		
Prime Partner Name: The Center for Community Health Research and Development		
Agreement Start Date: Redacted Agreement End Date: Redacted		
FBD: No  New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		

Approved



Funding Source F	Funding Amount
------------------	----------------

### Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	Strengthen In-Country Strategic Information Capacity for	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 14326	Mechanism Name: UCSF	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 150,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 150,000		
Funding Source	Funding Amount	
GHP-State	150,000	

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	105,000
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	45,000

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 14336	Mechanism Name: HMU follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hanoi Medical University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 454,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	

Total All Funding Sources and Applied Pipeline Amount: 454,000		
Funding Source Funding Amount		
GHP-State	454,000	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	14336	
Mechanism Name:	HMU follow on	
Prime Partner Name:	Hanoi Medical University	
Strategic Area	Budget Code	Planned Amount



Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	НКІД	0
Strategic Area	Budget Code	Planned Amount
Care	НУТВ	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	226,300
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	83,700
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	144,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
	Number of individuals who have been newly enrolled on	
PrEP_NEW_DSD	oral antiretroviral pre-exposure prophylaxis (PrEP) in	800
	the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Male 15-19	18
PrEP_NEW_DSD	Male 20-24	210
PrEP_NEW_DSD	Male 50+	12
PrEP_NEW_DSD	Female 15-19	6
PrEP_NEW_DSD	Female 20-24	70
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	720



PrEP_NEW_DSD	TG	40
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	70
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	210
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	32
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	96
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	36
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	18
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	40

# Implementing Mechanism Details

Mechanism ID: 16803	Mechanism Name: Healthy Markets	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Program for Appropriate Techr	nology in Health	
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,892,261	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,892,261		
Funding Source Funding Amount		
GHP-State	1,892,261	

### Cross-Cutting Budget Attribution(s)

(No data provided.)



# Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	e: Healthy Markets	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	350,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	961,928
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	580,333
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,600
PrEP_NEW_DSD	Male 15-19	58
PrEP_NEW_DSD	Male 20-24	680



PrEP_NEW_DSD	Male 50+	30
PrEP_NEW_DSD	Female 15-19	22
PrEP_NEW_DSD	Female 20-24	229
PrEP_NEW_DSD	Female 50+	15
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	2,340
PrEP_NEW_DSD	TG	132
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	229
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	680
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	104
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	311
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	42
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	120
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	22
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	58
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	128
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,040
PP_PREV_DSD	Age/sex: 10-14 Male	64
PP_PREV_DSD	Age/sex: 15-19 Male	64
PP_PREV_DSD	Age/sex: 20-24 Male	346
PP_PREV_DSD	Age/sex: 50+ Male	98
PP_PREV_DSD	Age/sex: 10-14 Female	20
PP_PREV_DSD	Age/sex: 15-19 Female	20
PP_PREV_DSD	Age/sex: 20-24 Female	117
PP_PREV_DSD	Age/sex: 50+ Female	41
PP_PREV_DSD	Sum of Age/Sex disaggregates	770
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	168
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	504
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	168



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	504
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	117
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	346
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	117
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	346
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,996
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,696
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,300
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for	68,648



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1,070
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,611
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	3,215
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	130
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	10,192
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	407
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	539
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	564
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	29
HTC_TST_DSD	By Key Population: FSW, Negative	3,721
HTC_TST_DSD	By Key Population: FSW, Positive	59
HTC_TST_DSD	By Key Population: MSM, Negative	8,812
HTC_TST_DSD	By Key Population: MSM, Positive	827
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	399
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	4



HTC_TST_DSD	By Key Population: PWID, Negative	12,694
HTC_TST_DSD	By Key Population: PWID, Positive	487
HTC_TST_DSD	By Key Population: TG, Negative	131
HTC_TST_DSD	By Key Population: TG, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	242
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	353
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	711
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2,256
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	181
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	952
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	2,256



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	836
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	2,136
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	165
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	470
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	952
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	242
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	242
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	4,298
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	172
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	10,192
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	407



HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative3,749HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive150HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative9,665HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative2,146HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative91HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTS_SELF_DSDHTS_SELF_N_DSD15,989HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_A			
HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive150HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative9,665HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive2,146HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative4,298HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD		3,749
HTC_TST_DSDMale, Negative9,665HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative2,146HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative4,298HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive1,070HTS_SELF_DSDHTS_SELF_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive1,070HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive1,070HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSe	HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34,	150
HTC_TST_DSDMale, Positive390HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative2,146HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative4,298HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted402	HTC_TST_DSD		9,665
HTC_TST_DSDFemale, Negative2,146HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative4,298HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD15,989HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD	_	390
HTC_TST_DSDFemale, Positive90HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative4,298HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD		2,146
HTC_TST_DSDMale, Negative4,298HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive1,070HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD	_	90
HTC_TST_DSDMale, Positive172HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative45HTS_SELF_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted262	HTC_TST_DSD		4,298
HTC_TST_DSDFemale, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive15,989HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD	_	172
HTC_TST_DSDFemale, Positive45HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_10trMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_Result 40-49, Male, Positive15,989HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD		1,070
HTC_TST_DSD1,070Male, Negative1,070HTC_TST_DSDHTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSD15,989HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted130HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted262HTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted402	HTC_TST_DSD	_	45
HTC_TST_DSD45Male, Positive45HTS_SELF_DSDHTS_SELF_N_DSDHTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-AssistedHTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, UnassistedHTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, UnassistedHTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Age_Sex_HIVSelfTest 15-19, HTS_SELF_DSDHTS_SELF_DSDHTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	HTC_TST_DSD		1,070
HTS_SELF_DSD       HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted       130         HTS_SELF_DSD       HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted       262         HTS_SELF_DSD       HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted       262         HTS_SELF_DSD       HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted       402	HTC_TST_DSD	_	45
HTS_SELF_DSD       Female, Directly-Assisted       130         HTS_SELF_DSD       HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted       262         HTS_SELF_DSD       HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted       402	HTS_SELF_DSD	HTS_SELF_N_DSD	15,989
HTS_SELF_DSD     262       HTS_SELF_DSD     Female, Unassisted     262       HTS_SELF_DSD     HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted     402	HTS_SELF_DSD		130
HTS_SELF_DSD 402 Male, Directly-Assisted	HTS_SELF_DSD	_	262
	HTS_SELF_DSD	_	402
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted 791	HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	791
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, 451	HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24,	451



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	869
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,343
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,610
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	477
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	927
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,421
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,779
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	262
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	499
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	771
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,504
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49,	34



	1	1
	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	34
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	74
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	5,416
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	10,573

### Implementing Mechanism Details

Mechanism ID: 17371	Mechanism Name: Health Finance & Governance (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

# Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: 17371			
Mechanism Name:	Health Finance & Governance (HFG)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	HVTB	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	OHSS	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HMBL	0	



Strategic Area	Budget Code	Planned Amount	
Prevention	HMIN	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVAB	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVCT	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	HVOP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	МТСТ	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 18149 Mechanism Name: CHP – HIV/AIDS Prevention
---



Applied Pipeline Amount: 0		
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
626. 110		
G2G: No	Managing Agency:	
Global Fund / Multilateral Engagement: N//	Ą	
TBD: No	New Mechanism: No	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
Prime Partner Name: Center for Communit	ty Health Promotion	
Funding Agency: DOD	Procurement Type: Grant	

Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### **Budget Code Information**

	18149 CHP – HIV/AIDS Prevention Center for Community Health Promotion	
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

Mechanism ID: 18172	Mechanism Name: Sustainable HIV Response from Technical Assistance (SHIFT) Project	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 4,058,871	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 4,058,871	
Funding Source	ce Funding Amount	
GHP-State	4,058,871	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID: Mechanism Name:	Sustainable HIV Response from Technical Assistance (SHIFT) Project	
Strategic Area	Budget Code	Planned Amount
Care	HBHC 3	
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	97,134
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	180,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	388,536
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,194,439
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	200,002
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,313,090
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	97,134

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	150
PrEP_NEW_DSD	Male 15-19	3
PrEP_NEW_DSD	Male 20-24	39
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	1
PrEP_NEW_DSD	Female 20-24	14
PrEP_NEW_DSD	Female 50+	0
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	135
PrEP_NEW_DSD	TG	8
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	14
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	39
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	6



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	18
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	1
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations	7
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,133
PP_PREV_DSD	Age/sex: 10-14 Male	387
PP_PREV_DSD	Age/sex: 15-19 Male	387
PP_PREV_DSD	Age/sex: 20-24 Male	1,929
PP_PREV_DSD	Age/sex: 50+ Male	629
PP_PREV_DSD	Age/sex: 10-14 Female	128
PP_PREV_DSD	Age/sex: 15-19 Female	128
PP_PREV_DSD	Age/sex: 20-24 Female	643
PP_PREV_DSD	Age/sex: 50+ Female	216
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,447
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	943
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,828
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	943
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,828
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	643
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,929
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	643
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,929
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,523
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key	9,433



		,
	populations reached with individual and/or small group	
	level HIV preventive interventions that are based on	
	evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,098
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,855
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	137
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	73,082
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	163
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	257
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24,	511



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	1,609
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	84
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	96
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	250
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	506
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,590
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	82
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female,	4



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	19
HTC_TST_DSD	By Key Population: FSW, Negative	3,957
HTC_TST_DSD	By Key Population: FSW, Positive	62
HTC_TST_DSD	By Key Population: MSM, Negative	9,374
HTC_TST_DSD	By Key Population: MSM, Positive	874
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	432
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	7
HTC_TST_DSD	By Key Population: PWID, Negative	13,515
HTC_TST_DSD	By Key Population: PWID, Positive	512
HTC_TST_DSD	By Key Population: TG, Negative	140
HTC_TST_DSD	By Key Population: TG, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	480
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	40



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,018
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,523
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,049
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,651
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	299
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	509
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	511
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	668



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,590
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	124
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	587
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,511
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	115
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	337
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	668
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	170
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	17



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	480
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	456
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	202
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	676
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	1,636



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	583
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	691
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	174
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	210
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,061
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	123
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	9,651
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	298



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,556
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	9,147
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	278
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,034
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,061
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	124
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,018
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,018
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	30
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	32,378
TX_CURR_DSD	Age/Sex: 15-19 Male	966
TX_CURR_DSD	Age/Sex: 15-19 Female	643
TX_CURR_DSD	Sum of age/sex disaggregates	1,609
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	100
TX_CURR_DSD	Age/Sex: 10-14 Male	41
TX_CURR_DSD	Age/Sex: 10-14 Female	50
TX_CURR_DSD	Age/Sex: 20-24 Male	5,795

Page 144 of 227

FACTS Info v3.8.24.1



TX_CURR_DSD	Age/Sex: 50+ Male	319
TX_CURR_DSD	Age/Sex: 20-24 Female	2,897
TX_CURR_DSD	Age/Sex: 50+ Female	322
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,897
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	5,473
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,575
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,151
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,288
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,575
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	643
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	643
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,316
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	12
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	161
TX_NEW_DSD	By Age/Sex: 20-24 Male	955
TX_NEW_DSD	By Age/Sex: 50+ Male	53
TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	104
TX_NEW_DSD	By Age/Sex: 20-24 Female	478
TX_NEW_DSD	By Age/Sex: 50+ Female	55
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,810
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	478



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	899
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	424
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	849
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	212
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	424
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	104
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	104
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	31,542
TX_PVLS_DSD	Denominator: Indication: Routine	31,542
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	488
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	19,869
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	488
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	10,697
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,280
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,534
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	794



		I
	adults and children who are still alive and on treatment	
	at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_DSD	adults and children who are still alive and on treatment	1,472
	at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number	
TX_RET_DSD	of adults and children who are still alive and on	10
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_DSD	of adults and children who are still alive and on	4
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	882
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	1,636
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	12
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	4
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	17,437
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	148
	Female, Directly-Assisted	140
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	286



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	444
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	864
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	491
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	950
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,468
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,848
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	517
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,008
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,555
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3,020
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	283
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	545
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	848
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,650
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	45



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	90
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	26
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	88
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	37
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	83
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	5,921
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	11,516
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,723
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	29
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	29
*		•



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	684
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,285
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	26
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	26
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	583
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,088
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	431
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	29,142
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	144
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	279
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	455
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	455
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	9,883
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	18,349

# Implementing Mechanism Details

Mechanism ID: 18173	Mechanism Name: USAID Enhanced Community HIV Link- Southern Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Center for Promotion of Quality	y of Life	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 490,540	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipe	eline Amount: 490,540
Funding Source	Funding Amount

Approved



GHP-State	490,540

#### Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Budget Code Information**

Machaniam ID:	40470	
Mechanism ID: 18173		
	USAID Enhanced Community HIV Link- Southern Project	
Prime Partner Name:	Center for Promotion of Quality	of Life
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	110,000
Strategic Area	Budget Code	Planned Amount

Custom 2018-09-07 15:52 EDT Page 151 of 227

FACTS Info v3.8.24.1



Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	380,540
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,200
PP_PREV_DSD	Age/sex: 10-14 Male	296
PP_PREV_DSD	Age/sex: 15-19 Male	296
PP_PREV_DSD	Age/sex: 20-24 Male	1,484
PP_PREV_DSD	Age/sex: 50+ Male	488
PP_PREV_DSD	Age/sex: 10-14 Female	100
PP_PREV_DSD	Age/sex: 15-19 Female	100
PP_PREV_DSD	Age/sex: 20-24 Female	496
PP_PREV_DSD	Age/sex: 50+ Female	164
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,424
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	728
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,180
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	728
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,180
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	496
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,484
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	496
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,484
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	15,022
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,051
KP_PREV_DSD	By key population type: Transgender who are NOT sex	1,035



		1
	workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	687
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	249
TX_CURR_DSD	Age/Sex: 15-19 Male	0
TX_CURR_DSD	Age/Sex: 15-19 Female	0
TX_CURR_DSD	Sum of age/sex disaggregates	0
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	0
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	0



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	0

#### Implementing Mechanism Details

Mechanism ID: 18194	Mechanism Name: Global Health Supply Chain Program (GHSCP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
[	

Total All Funding Sources: 466,581	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 843,419		
Total All Funding Sources and Applied Pipeline Amount: 1,310,000		
Funding Source Funding Amount		
GHP-State	466,581	

#### Cross-Cutting Budget Attribution(s)

(No data provided.)



# **Budget Code Information**

Mechanism Name:	Mechanism ID: 18194 Mechanism Name: Global Health Supply Chain Program (GHSCP) Prime Partner Name: Global Health Supply Chain Program	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	466,581
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 18271	Mechanism Name: Department of Health HCMC	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ho Chi Minh City Department of Health		



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
- -		
Total All Funding Sources: 1,428,187	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 550,000		
Total All Funding Sources and Applied Pipeline Amount: 1,978,187		
Funding Source	Funding Amount	
GHP-State	1,428,187	

### Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Budget Code Information**

Baagot oodo information		
Mechanism ID:	18271	
Mechanism Name:	Department of Health HCMC	
Prime Partner Name:	Ho Chi Minh City Department of	Health
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	454,953
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	290,804
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	682,430
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,500
PrEP_NEW_DSD	Male 15-19	35
PrEP_NEW_DSD	Male 20-24	396
PrEP_NEW_DSD	Male 50+	16
PrEP_NEW_DSD	Female 15-19	11
PrEP_NEW_DSD	Female 20-24	133
PrEP_NEW_DSD	Female 50+	11
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	1,350
PrEP_NEW_DSD	TG	76
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	133
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	396
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	61
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	179
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	65
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	11
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	30
PrEP_NEW_DSD	PrEP_NEW_N_DSD_KeyPopAbr Other Key	74

Custom 2018-09-07 15:52 EDT Page 160 of 227

FACTS Info v3.8.24.1



	Populations	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,200
PP_PREV_DSD	Age/sex: 10-14 Male	114
PP_PREV_DSD	Age/sex: 15-19 Male	114
PP_PREV_DSD	Age/sex: 20-24 Male	586
PP_PREV_DSD	Age/sex: 50+ Male	180
PP_PREV_DSD	Age/sex: 10-14 Female	39
PP_PREV_DSD	Age/sex: 15-19 Female	39
PP_PREV_DSD	Age/sex: 20-24 Female	200
PP_PREV_DSD	Age/sex: 50+ Female	66
PP_PREV_DSD	Sum of Age/Sex disaggregates	1,338
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	286
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	859
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	286
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	859
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	200
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	586
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	200
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	586
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,132
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,330
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	172



	preventive interventions that are based on evidence	
	and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,734
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,375
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	521
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,141
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	69
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	222
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	18



	Male D. W	
	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	121
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	240
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	758
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	6
HTC_TST_DSD	By Key Population: FSW, Negative	871



HTC_TST_DSD	By Key Population: FSW, Positive	14
HTC_TST_DSD	By Key Population: MSM, Negative	2,072
HTC_TST_DSD	By Key Population: MSM, Positive	190
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	113
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	2,979
HTC_TST_DSD	By Key Population: PWID, Positive	112
HTC_TST_DSD	By Key Population: TG, Negative	26
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	198
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	294
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	589
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,863
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male,	10

Page 164 of 227

FACTS Info v3.8.24.1



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	758
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	715
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	59
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29,	93



	Francis Neverla	
	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	222
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	210
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	788
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29,	60



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,863
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	685
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,767
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	133
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	391
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	788
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	198
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	198
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	14
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,535
TX_CURR_DSD	Age/Sex: 15-19 Male	472
TX_CURR_DSD	Age/Sex: 15-19 Female	313
TX_CURR_DSD	Sum of age/sex disaggregates	785



TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	411
TX_CURR_DSD	Age/Sex: 10-14 Male	205
TX_CURR_DSD	Age/Sex: 10-14 Female	206
TX_CURR_DSD	Age/Sex: 20-24 Male	2,829
TX_CURR_DSD	Age/Sex: 50+ Male	158
TX_CURR_DSD	Age/Sex: 20-24 Female	1,413
TX_CURR_DSD	Age/Sex: 50+ Female	159
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,413
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,670
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,258
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,517
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	627
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,258
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	313
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	313
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,671
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	21
TX_NEW_DSD	By Age/Sex: 10-14 Male	9
TX_NEW_DSD	By Age/Sex: 15-19 Male	48
TX_NEW_DSD	By Age/Sex: 20-24 Male	293
TX_NEW_DSD	By Age/Sex: 50+ Male	18
TX_NEW_DSD	By Age/Sex: 10-14 Female	11



TX_NEW_DSD	By Age/Sex: 15-19 Female	33
TX_NEW_DSD	By Age/Sex: 20-24 Female	146
TX_NEW_DSD	By Age/Sex: 50+ Female	16
TX_NEW_DSD	Sum of Age/Sex disaggregates	574
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	147
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	277
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	131
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	260
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	65
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	130
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	33
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	33
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	16,567
TX_PVLS_DSD	Denominator: Indication: Routine	16,567
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	257
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,435
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	257
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,618
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,027



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,141
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	341
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	642
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	385
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	708
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	23



	stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	2,475
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	22
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	37
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	117
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	138
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	211
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	408
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	73
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	139
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	219
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	430
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	37
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	117
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	233



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	31
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	834
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,641
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	776
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period	913



		[]	
	but had not been reported as they did not fulfill the		
	minimum requirements for the previous reporting		
	period).		
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	15	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	15	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	308	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	575	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	13	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	13	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	264	
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	486	
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	248	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	14,883	
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0	
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0	
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	82	
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	166	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	230	
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	230	
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	5,046	
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	9,377	

# Implementing Mechanism Details

Mechanism ID: 18541	TBD: Yes
REDACTED	

#### Implementing Mechanism Details

Mechanism ID: 18616	Mechanism Name: USAID Enhanced Community HIV Link - Northern	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	



Prime Partner Name: CENTER FOR COMMUNITY HEALTH RESEARCH AND DEVELOPMENT			
eement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No Managing Agency:			
Fotal All Funding Sources: 939,200       Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 939,200			
Funding Source Funding Amount			
HP-State 939,200			

# Cross-Cutting Budget Attribution(s)

(No data provided.)

# **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:	USAID Enhanced Community HIV Link - Northern CENTER FOR COMMUNITY HEALTH RESEARCH AND	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	80,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	552,020
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	307,180
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Indicator Number	Label	2019
	Number of the target population who completed a	
PP_PREV_DSD	standardized HIV prevention intervention including the	21,262
	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Male	477
PP_PREV_DSD	Age/sex: 15-19 Male	477
PP_PREV_DSD	Age/sex: 20-24 Male	2,391
PP_PREV_DSD	Age/sex: 50+ Male	803
PP_PREV_DSD	Age/sex: 10-14 Female	158
PP_PREV_DSD	Age/sex: 15-19 Female	158
PP_PREV_DSD	Age/sex: 20-24 Female	798
PP_PREV_DSD	Age/sex: 50+ Female	264
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,526
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,170
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,509
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,170
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,509
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	798
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,391
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	798

Custom 2018-09-07 15:52 EDT Page 176 of 227

FACTS Info v3.8.24.1



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,391
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	21,786
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,955
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,491
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,487
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,991
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	862

# Implementing Mechanism Details

Mechanism ID: 18618	Mechanism Name	Mechanism Name: Recovery Plus	
Funding Agency: HHS/SAMHSA         Procurement Type: Cooperative Agreement		Cooperative Agreement	
Prime Partner Name:			
CENTRE FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES			
Custom	Page 177 of 227 FACTS Info v3.8.		

2018-09-07 15:52 EDT



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Fotal All Funding Sources: 254,000     Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 254,000		
Funding Source	Funding Amount	
GHP-State	254,000	

### Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Budget Code Information**

	18618	
Mechanism ID:	Recovery Plus	
Mechanism Name:	•	
	CENTRE FOR SUPPORTING COM	
	INITIATIVES	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	35,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	219,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 18619	Mechanism Name: Vietnam HIV-Addiction Technology Transfer Center		
Funding Agency: HHS/SAMHSA	Procurement Type: Cooperative Agreement		
Prime Partner Name: University of California a	at Los Angeles		
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 416,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 416,000			
Funding Source Funding Amount			

#### Cross-Cutting Budget Attribution(s)

(No data provided.)

GHP-State

416,000



Mechanism ID: 18619		
Mechanism Name:	Vietnam HIV-Addiction Technology Transfer Center	
Prime Partner Name:	University of California at Los Angeles	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	126,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	290,000
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 18620	Mechanism Name: FHI - Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Funding Source	Funding Amount	
Total All Funding Sources and Applied Pipeline Amount: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
G2G: No	Managing Agency:	
Global Fund / Multilateral Engagement: N/		
TBD: No	New Mechanism: No	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
Prime Partner Name: FHI 360		

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	FHI - Lab	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 70416	Mechanism Name: [Placeholder - 70416 Vietnam DOD]	
Funding Agency: DOD	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/	A	
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	

Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)



# Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	e: [Placeholder - 70416 Vietnam DOD]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount

Custom 2018-09-07 15:52 EDT Page 186 of 227

FACTS Info v3.8.24.1



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70417	Mechanism Name: [Placeholder - 70417 Vietnam DOD]
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Applied Pipeline Amount: 0 Total All Funding Sources and Applied Pipeline A	mount: 0

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	: [Placeholder - 70417 Vietnam DOD]	
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 70418	Mechanism Name: [Placeholder - 70418 Vietnam HHS/CDC]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0 Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

# **Budget Code Information**



Mechanism ID: 70418 Mechanism Name: [Placeholder - 70418 Vietnam HHS/CDC] Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70419	Mechanism Name: [Placeholder - 70419 Vietnam HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N/A	A
G2G: No Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied I	Pipeline Amount: 0
Funding Source	Funding Amount

(No data provided.)

Budget bode information		
Mechanism ID:	70419	
Mechanism Name:	[Placeholder - 70419 Vietnam HHS/CDC]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 70420	Mechanism Name: [Placeholder - 70420 Vietnam HHS/CDC]
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Budget Code Information**

Mechanism ID: 70420



Mechanism Name: Prime Partner Name:	-	HS/CDC]
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70421	Mechanism Name: [Placeholder - 70421 Vietnam HHS/HRSA]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount

(No data provided.)

Mechanism ID: 70421		
Mechanism Name:	[Placeholder - 70421 Vietnam HHS/HRSA]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

# **Implementing Mechanism Details**

Mechanism ID: 70422	Mechanism Name: [Placeholder - 70422 Vietnam HHS/HRSA]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/	A	
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		

Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	70422
Mechanism Name:	[Placeholder - 70422 Vietnam HHS/HRSA]
Prime Partner Name:	[Placeholder]



Strategic Area	Budget Code	Planned Amount
Care	НВНС	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70423	Mechanism Name: [Placeholder - 70423 Vietnam HHS/SAMHSA]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

(No data provided.)

Budget Code Information			
Mechanism ID:	Mechanism ID: 70423		
Mechanism Name:	[Placeholder - 70423 Vietnam HHS/SAMHSA]		
Prime Partner Name:			
Strategic Area	Budget Code	Planned Amount	
Care	НВНС	0	
Strategic Area	Budget Code	Planned Amount	
Care	HKID	0	
Strategic Area	Budget Code	Planned Amount	
Care	НУТВ	0	
Strategic Area	Budget Code	Planned Amount	
Care	PDCS	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HLAB	0	
Strategic Area	Budget Code	Planned Amount	
Governance and Systems	HVSI	0	



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



|--|

(No data provided.)

# **Implementing Mechanism Details**

echanism ID: 70424 HHS/SAMHSA]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	

Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	70424	
Mechanism Name:	[Placeholder - 70424 Vietnam Hl	HS/SAMHSA]
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 70425	Mechanism Name: [Placeholder - 70425 Vietnam HHS/SAMHSA]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: 70425		
Mechanism Name:	Mechanism Name: [Placeholder - 70425 Vietnam HHS/SAMHSA]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 70426	Mechanism Name: [Placeholder - 70426 Vietnam HHS/SAMHSA]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
2G: No Managing Agency:		
otal All Funding Sources: 0 Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
unding Source Funding Amount		

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	70426	
Mechanism Name:	[Placeholder - 70426 Vietnam HHS/SAMHSA]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 70427	TBD: Yes
REDACTED	

Mechanism ID: 70428	Mechanism Name: [Placeholder - 70428 Vietnam USAID]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID:	hanism ID: 70428	
Mechanism Name:	[Placeholder - 70428 Vietnam USAID]	
Prime Partner Name:		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



|--|

(No data provided.)

# **Implementing Mechanism Details**

Mechanism ID: 70429	Mechanism Name: [Placeholder - 70429 Vietnam USAID]	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		

Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	70429	
Mechanism Name:	[Placeholder - 70429 Vietnam USAID]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

(No data provided.)

Mechanism ID: 70430	Mechanism Name: [Placeholder - 70430 Vietnam USAID]	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: [Placeholder]		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	

(No data provided.)

Mechanism ID: 70430		
Mechanism Name:	lame: [Placeholder - 70430 Vietnam USAID]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	НУТВ	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	МТСТ	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 70431	Mechanism Name: [Placeholder - 70431 Vietnam USAID]		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: [Placeholder]			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pi	peline Amount: 0		
Funding Source Funding Amount			

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	70431				
Mechanism Name:	[Placeholder - 70431 Vietnam USAID]				
Prime Partner Name:	[Placeholder]				
Strategic Area	Budget Code Planned Amount				
Care	HBHC	0			
Strategic Area	Budget Code	Planned Amount			



Care	НКІД	0
Strategic Area	Budget Code	Planned Amount
Care	НУТВ	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code Planned Amount		
Prevention	IDUP	0	
Strategic Area	Budget Code	Planned Amount	
Prevention	МТСТ	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXD	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	HTXS	0	
Strategic Area	Budget Code	Planned Amount	
Treatment	PDTX	0	

(No data provided.)

Mechanism ID: 70520	TBD: Yes
REDA	CTED



# Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		143,530		143,530	0	143,530
ICASS		372,502		372,502	0	372,502
Non-ICASS Administrative Costs		215,639		215,639	0	215,639
Staff Program Travel		350,000		350,000	0	350,000
USG Staff Salaries and Benefits - Internationally Recruited		1,183,354		1,183,354	0	1,183,354
USG Staff Salaries and Benefits - Locally Recruited		585,503		585,503	0	585,503
Total	0	2,850,528	0	2,850,528	0	2,850,528

# **U.S.** Department of Defense

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
Computers/IT Services		3,100		3,100	6,900	10,000
ICASS		34,100		34,100	75,900	110,000
Institutional Contractors				0	13,800	13,800
Management Meetings/Profes sional Development		12,400		12,400	27,600	40,000
Non-ICASS Administrative Costs		4,650		4,650	10,350	15,000
Non-ICASS Motor Vehicles		1,550		1,550	3,450	5,000
Staff Program Travel		37,371		37,371	68,829	106,200
USG Renovation		3,100		3,100	6,900	10,000
USG Staff Salaries and Benefits - Locally Recruited		53,717		53,717	119,564	173,281
Total	0	149,988	0	149,988	333,293	483,281

# U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All
Custom		Pa	age 224 of 227		FACTS	S Info v3.8.24.1



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		763,579		763,579	0	763,579
Computers/IT Services		135,637		135,637	0	135,637
ICASS		1,371,184		1,371,184	0	1,371,184
Institutional Contractors		365,546		365,546	0	365,546
Management Meetings/Profes sional Development		125,000		125,000	0	125,000
Non-ICASS Administrative Costs		332,146		332,146	0	332,146
Non-ICASS Motor Vehicles		13,181		13,181	0	13,181
Staff Program Travel		375,000		375,000	0	375,000
USG Staff Salaries and Benefits - Internationally Recruited	344,012	365,615		709,627	1,000,000	1,709,627
USG Staff Salaries and Benefits - Locally Recruited	1,513,738	0		1,513,738	0	1,513,738
Total	1,857,750	3,846,888	0	5,704,638	1,000,000	6,704,638



# U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security		33,000		33,000	0	33,000
Cost Sharing Computers/IT Services		15,000		15,000	0	15,000
ICASS		95,000		95,000	0	95,000
Management Meetings/Profes sional Development		14,500		14,500	0	14,500
Non-ICASS Administrative Costs		25,000		25,000	0	25,000
Staff Program Travel		86,771		86,771	0	86,771
USG Staff Salaries and Benefits - Internationally Recruited		270,460		270,460	0	270,460
USG Staff Salaries and Benefits - Locally Recruited		155,772		155,772	0	155,772
Total	0	695,503	0	695,503	0	695,503

Custom 2018-09-07 15:52 EDT Page 226 of 227

FACTS Info v3.8.24.1



# U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		15,000		15,000	0	15,000
ICASS		130,000		130,000	0	130,000
Management Meetings/Profes sional Development		50,000		50,000	0	50,000
Non-ICASS Administrative Costs		210,000		210,000	0	210,000
Staff Program Travel		70,000		70,000	0	70,000
USG Renovation		30,000		30,000	0	30,000
USG Staff Salaries and Benefits - Locally Recruited		120,000		120,000	0	120,000
Total	0	625,000	0	625,000	0	625,000